Fosamprenavir

This classification denotes a protease inhibitor with the molecular formula C25H36N3O9PS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WOU1621EEG, chemically known as carbamic acid, ((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, c-((3s)-tetrahydro-3-furanyl) ester but generally known as fosamprenavir, which bears US NIH Compound Identifier 131536. European Medicines Agency schedules Fosamprenavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25386. The term FOSAMPRENAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules fosamprenavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule fosamprenavir under HS 29350090 and SITC 51580. As of Q4 2014, FOSAMPRENAVIR remains the US FDA Preferred Term for this commodity. Fosamprenavir bears US NLM identifiers UMLS ID C1176315 and NCI Concept Code C83720. SMILES: S(=O)(=O)(N(CC(OP(=O)(O)O)C(NC(=O)OC1CCOC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1.